MU Engineer Develops Improved Landmine Detectors Reserach at MU, MO - Nov 5, 2008 The Mizzou researchers delivered the therapy to the hearts of newborn mice with muscular dystrophy and found that gene therapy corrected many of the ...
Scientists find promising areas in new research Jackson Clarion Ledger, MS - Nov 15, 2008 Although such tales horrify, Kunkel believes viruses can play an important role in gene therapy. One other possible approach is gene repair in muscular...
Muscular Dystrophy: Sarcospan, A Little Protein For A Big Problem Science Daily (press release) - Nov 11, 2008 ... were protected by sarcospan, but the true importance of this discovery will lie in its potential for human therapeutics, specifically gene therapy. ...
5 of 8 children in North Logan have have MD KUTV, UT - Nov 15, 2008 MDA considers the finding significant because treating diseases like DMD with gene therapy is likely to require that the therapy reach all muscles after the ...
A New Option for Migraine Treatment on the Horizon HealthNews, CA - Nov 27, 2008 Telcagepant is from a different drug class known as calcitonin gene-related peptide (CGRP) antagonists. Because it is believed that levels of CGRP in the ...
Patient, heal thyself: Grow your own new organ Independent, UK - Nov 21, 2008 He was one of the first three patients with eye disorders to be treated with gene therapy ? an injection of normal versions of the defective gene that ...
UI study may explain exercise-induced fatigue in muscular... exduco.net, Italy - Nov 18, 2008 The team also found that although gene therapy could restore the structure and function of an important component of muscle membranes in mice with muscular...
Source: Google News
Recent News and Articles on the Keywords: muscular dystrophy + gene therapy + gene Related to the article below (Last Update: 8/7/2008)
Gene doping Fairly safe Economist, UK - Jul 31, 2008 This is especially true of gene therapy. Replacing defective genes holds out great promise for people suffering from diseases such as muscular dystrophy and ...
Safeway Launches Annual Fundraising Campaign for MDA WELT ONLINE, Germany - Aug 1, 2008 MDA scientists are in the forefront of gene therapy research and have uncovered the genetic defects responsible for several forms of muscular dystrophy, ...SWY
PTC and Genzyme in $437M Gene Therapy Deal Seeking Alpha, NY - Jul 20, 2008 In phase 2a clinical trials in nonsense-mutation-mediated cystic fibrosis and in nonsense-mutation-mediated Duchenne muscular dystrophy, ...GENZ
Belton Swim Center goes therapeutic Belton Journal, TX - Jul 19, 2008 In the early 1990s, researchers identified the gene for the protein dystrophin which, when absent, causes DMD. The dystrophin gene is the largest known gene...
[PDF]Advances in Duchenne muscular dystrophy gene therapy - JCT van Deutekom, GJB van Ommen - Nature Reviews Genetics, 2003 - duchenne.plant.nl ... Table 1 | Overview of strategies for Duchenne musculardystrophygenetherapy
Strategy Action/effect Advantages Disadvantages Prospects ... -
Gene therapy of muscular dystrophy - JS Chamberlain - Human Molecular Genetics, 2002 - Oxford Univ Press ...Genetherapy of musculardystrophy. ... 29 Hartigan-O'Connor, D. and Chamberlain, JS
(2000) Developments in genetherapy for musculardystrophy. Microsc. Res. ...
Gene Transfer in Regenerating Muscle - M Vitadello, MV Schiaffino, A Picard, M Scarpa, S … - Human Gene Therapy, 1994 - liebertonline.com ... regenerating muscle fibers display a higher efficiency of transfection may be relevant
to genetherapy of Duchenne musculardystrophy, because regenerating ...
Dystrophin expression in the mdx mouse restored by stem cell transplantation. - E Gussoni, Y Soneoka, CD Strickland, EA Buzney, MK … - Nature, 1999 - ncbi.nlm.nih.gov ... The development of cell or gene therapies for diseases involving cells that ... in the
mdx mouse, an animal model of Duchenne's musculardystrophy, which indicate ...
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin - SB England, LVB Nicholson, MA Johnson, SM Forrest, … - Nature, 1990 - palgrave-journals.com ... DUCHENNE musculardystrophy (DMD) 1 and Becker musculardystrophy (BMD), a much ... results
are particularly significant in the context of genetherapy which, if ...
First ever gene therapy success for congenital muscular dystrophy achieved
Researchers at the University of Pittsburgh reported the first study to achieve success with gene therapy for the treatment of congenital muscular dystrophy ( CMD ) in mice.
Moreover, their results, published in the Proceedings of the National Academy of Sciences ( PNAS ), indicate that a single treatment can have expansive reach to muscles throughout the body and significantly increase survival.
CMD is a group of some 20 inherited muscular dystrophies characterized by progressive and severe muscle wasting and weakness first noticed soon after birth. No effective treatments exist and children usually die quite young.
Despite gene therapy being among the most vigorously studied approaches for muscular dystrophy, it has been beset with uniquely difficult hurdles.
The genes to replace those that are defective in CMD are larger than most, so it has not been possible to apply the same methods successfully used for delivering other types of genes.
And because CMD affects all muscles, an organ that accounts for 40 percent of body weight, gene therapy can only have real therapeutic benefit if it is able to reverse genetic defects in every cell of the body's 600 muscle groups.
By using a miniature gene, similar in function to the one defective in CMD, and applying a newly developed method for "systemic" gene delivery, the researchers have shown that gene therapy for muscular dystrophy is both feasible and effective in a mouse model of especially profound disease.
Using this approach, the team, led by Xiao Xiao, reported that treated mice had physiological improvements in the muscles of the heart, diaphragm, abdomen and legs; and they grew faster, were physically more active and lived four times as long as untreated animals.
" While we have much farther to go until we can say gene therapy will work in children, we have shown here a glimmer of hope by presenting the first evidence of a successful gene therapy approach that improved both the general health and longevity in mice with congenital muscular dystrophy," said Xiao.
The most common form of CMD, and also one of the most severe, is due to a genetic mutation of laminin alpha-2, a protein that is essential for maintaining the structures that surround muscle cells and is an integral link in the chain of proteins that regulate the cell's normal contraction and relaxation. If the protein is defective, or is lacking, this outside scaffold, called the extra-cellular matrix, disintegrates, and the muscle cells become vulnerable to damage.
Simply replacing the defective gene with a good laminin alpha-2 gene is not possible because its size makes it impossible for researchers to get it to squeeze inside viral vectors – disarmed viruses that are used to shuttle genes into cells. But the team found a good stand-in in a similar protein called agrin that when miniaturized could be inserted inside an adeno-associated virus ( AAV ) vector.
In the current study, the authors showed that two strains of AAV, AAV-1 and AAV-2, were effective in transferring the mini-agrin gene to cells in two mouse models.
The AAV-1 vector was given by systemic delivery – a single infusion into the abdominal cavity – a method the authors only recently described and which they used for the first time in this study to transfer a therapeutic gene.
The AAV-2 vector was delivered locally, given by intramuscular injection to different muscles of the leg.
With both approaches, muscle cells were able to assimilate and copy the genetic instructions for making mini-agrin.
Once produced, the mini-agrin protein functionally took the place of the laminin alpha-2 protein by binding to the key proteins on either end, thus restoring the cell's outside scaffolding and reestablishing the missing link to key structures inside the cell.
" It's probably not realistic to expect that we can achieve complete success using the mini-agrin gene, which while somewhat similar, is structurally unrelated to laminin alpha-2. Unless we address the underlying cause of congenital muscular dystrophy we're not likely to be able to completely arrest or cure CMD," added Chungping Qiao, the study's first author.
Future directions for research include finding a way to engineer the laminin alpha-2 gene. For this study, the authors chose to use the mini-agrin gene because researchers from the University of Basel, Switzerland, had already demonstrated it could improve the symptoms of muscular dystrophy in a transgenic mouse model, which has little clinical relevance.
Source: University of Pittsburgh Medical Center, 2005
